Trials / Completed
CompletedNCT03898791
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3295668 Erbumine | oral capsules |
Timeline
- Start date
- 2019-07-16
- Primary completion
- 2020-06-02
- Completion
- 2021-03-30
- First posted
- 2019-04-02
- Last updated
- 2021-08-05
Locations
40 sites across 8 countries: United States, Belgium, France, Japan, South Korea, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03898791. Inclusion in this directory is not an endorsement.